Leukocyte apheresis in the management of ulcerative colitis
- PMID: 19794281
- PMCID: PMC2981852
- DOI: 10.4103/1319-3767.56093
Leukocyte apheresis in the management of ulcerative colitis
Abstract
Ulcerative colitis is a chronic inflammatory disease that affects the colon and rectum. Its pathogenesis is probably multifactorial including the influx of certain cytokines into the colonic mucosa, causing disease activity and relapse. The hypothesis of removing such cytokines from the circulation by leukocytapheresis was implemented to reduce disease activity, maintain remission, and prevent relapse. Many recent reports not only in Japan, but also in the West, have highlighted its beneficial effects in both adult and pediatric patients. Large placebo-controlled studies are needed to confirm the available data in this regard. In this article, we shed some light on the use of leukocyte apheresis in the management of autoimmune diseases, especially ulcerative colitis.
Conflict of interest statement
Figures
Similar articles
-
Successful treatment of ulcerative colitis with leukocytapheresis using non-woven polyester filter.Ther Apher Dial. 2003 Dec;7(6):536-9. doi: 10.1046/j.1526-0968.2003.00096.x. Ther Apher Dial. 2003. PMID: 15018240
-
Centrifugal leukocyte apheresis for ulcerative colitis.Ther Apher. 1998 May;2(2):125-8. doi: 10.1111/j.1744-9987.1998.tb00089.x. Ther Apher. 1998. PMID: 10225713
-
Addition of leukocytapheresis to steroid therapy: is it beneficial in recurrence of moderate-to-severe ulcerative colitis?Dis Colon Rectum. 2003 Oct;46(10 Suppl):S3-9. doi: 10.1097/01.DCR.0000088851.79497.9B. Dis Colon Rectum. 2003. PMID: 14530652
-
Leukocytapheresis for the treatment of IBD.Nat Clin Pract Gastroenterol Hepatol. 2008 Sep;5(9):509-16. doi: 10.1038/ncpgasthep1209. Epub 2008 Jul 29. Nat Clin Pract Gastroenterol Hepatol. 2008. PMID: 18665138 Review.
-
Selective leukocyte apheresis for the treatment of inflammatory bowel disease.J Clin Gastroenterol. 2007 Nov-Dec;41(10):874-88. doi: 10.1097/MCG.0b013e3180479435. J Clin Gastroenterol. 2007. PMID: 18090155 Review.
Cited by
-
LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS.Acta Clin Croat. 2019 Sep;58(3):529-534. doi: 10.20471/acc.2019.58.03.18. Acta Clin Croat. 2019. PMID: 31969767 Free PMC article.
References
-
- Loftus EV., Jr Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17. - PubMed
-
- Oxelmark L, Hillerås P, Dignass A, Mössner J, Schreiber S, Kruis W, et al. Quality of life in patients with active ulcerative colitis treated with selective leukocyte apheresis. Scand J Gastroenterol. 2007;42:406–7. - PubMed
-
- Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci. 1983;28:833–42. - PubMed
-
- Present DH. How to do without steroids in inflammatory bowel disease? Inflamm Bowel Dis. 2000;6:48–57. - PubMed
-
- Schreiber S, Nikolaus S, Hampe J, Hämling J, Koop I, Groessner B, et al. Tumour necrosis factor alpha and interleukin 1 beta in relapse of Crohn's disease. Lancet. 1999;353:459–61. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical